Cargando…
Discovery and development of Factor Xa inhibitors (2015–2022)
As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT). And anticoagulant drugs are one of the most effective ways to prevent and treat these dise...
Autores principales: | Zheng, Wei, Dai, Xiaoqin, Xu, Binyao, Tian, Wei, Shi, Jianyou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993480/ https://www.ncbi.nlm.nih.gov/pubmed/36909153 http://dx.doi.org/10.3389/fphar.2023.1105880 |
Ejemplares similares
-
Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions
por: Meng, Long, et al.
Publicado: (2022) -
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials
por: Qu, Wei, et al.
Publicado: (2021) -
Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022) -
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011) -
The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)